Tanja Frey

Tanja Frey

Auto-generated profile, based on publicly available information

Tanja Frey

Institut für Medizinische Genetik, Universität Zürich Schlieren Switzerland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Neurology Genetics
Verified
Journal Article
Open access
ACAngela Clara-Hwang
Angela Clara-Hwang
SSStefani Stefani
Stefani Stefani
TLTracy Lau
Tracy Lau
MSMarcello Scala
Marcello Scala
BABüşra Aynekin
Büşra Aynekin
Stephanie EfthymiouStephanie Efthymiou
Stephanie Efthymiou
To present a case series of novel CHD2 variants in patients presenting with genetic epileptic and developmental encephalopathy. CHD2 gene encodes an ATP-dependent enzyme, chromodomain helicase DNA-binding protein 2, involved in chromatin remodeling. Pathogenic variants in CHD2 are linked to early-onset conditions such as developmental and epileptic encephalopathy, drug-resistant epilepsies, and neurodevelopmental disorders. Approximately 225 diagnosed patients from 28 countries exhibit various allelic variants in CHD2, including small intragenic deletions/insertions and missense, nonsense, and splice site variants. We present the molecular and clinical characteristics of 17 unreported individuals from 17 families with novel pathogenic or likely pathogenic variants in CHD2. All individuals presented with severe global developmental delay, childhood-onset myoclonic epilepsy, and additional neuropsychiatric features, such as behavioral including autism, ADHD, and hyperactivity. Additional findings include abnormal reflexes, hypotonia and hypertonia, motor impairment, gastrointestinal problems, and kyphoscoliosis. Neuroimaging features included hippocampal signal alterations (4/10), with additional volume loss in 2 cases, inferior vermis hypoplasia (7/10), mild cerebellar atrophy (4/10), and cerebral atrophy (1/10). Our study broadens the geographic scope of CHD2-related phenotypes, providing valuable insights into the prevalence and clinical characteristics of this genetic disorder in previously underrepresented populations.

24 November 2017 in Cancer Causes & Control
Verified
Journal Article
Closed access
PDF file
TFTanja Frey
Tanja Frey
EPElizabeth A. Platz
Elizabeth A. Platz
NKNorma Kanarek
Norma Kanarek
GBGary Bradwin
Gary Bradwin
ADAdrian S. Dobs
Adrian S. Dobs
Sabine ROHRMANNSabine ROHRMANN
Sabine ROHRMANN

4 July 2023 in Developmental Neurorehabilitation
Verified
Journal Article
Open access
NKNikolai Kiselev
Nikolai Kiselev
TFTanja Frey
Tanja Frey
ANAnnika Naesbom
Annika Naesbom
RPReto Planzer
Reto Planzer
AMAndreas David Meyer-Heim
Andreas David Meyer-Heim
AimInvestigation of the perspectives of paediatric health care professionals (PHCPs) in Switzerland regarding factors that influence participation in physical activity programs for children and adolescents with disabilities or chronic conditions (CADCCs). Evaluation of self-reported exercise counselling behavior of those professionals.MethodA cross-sectional survey was used to collect the opinions of 171 PHCPs working with CADCCs using a structured questionnaire. The information obtained was evaluated by performing a combined quantitative and qualitative statistical analysis.ResultsPHCPs in Switzerland think that CADCC do not get enough physical activity and see the underlying reasons in lacking information/knowledge and organizational factors. We found that the level of knowledge about disability sports opportunities among PHCPs has a positive influence on their exercise counselling behaviour.ConclusionsWe propose three approaches to increase the level of physical activity in CADCC: Establishing personalized exercise counseling, intensifying information about disability sports programmes towards PHCPs, and improving inclusion and integration in PE lessons or regular sports clubs.

12 May 2026
Verified
Book
Closed access
TFTanja Frey
Tanja Frey
VGVanessa Grand
Vanessa Grand
MGMarinella Gugliotta
Marinella Gugliotta
BLBianca Link
Bianca Link
ILIlaria Luperi
Ilaria Luperi
OWOlivia Wälti
Olivia Wälti
Was sind Seltene Krankheiten? Auf diese und viele weitere Fragen zur rechtlichen, ethischen und medizinischen Beurteilung von seltenen Krankheiten gibt der Sammelband Antworten aus Wissenschaft und Praxis. Er fördert gerade auch das Verständnis juristischer Rahmenbedingungen bei der Diagnose und Therapie sowie dem medizinischen Alltag in Bezug auf Seltene Krankheiten, zeigt die Perspektiven von Betroffenen auf, erläutert nationale Bestrebungen. Der Sammelband gibt Einblicke in eine komplexe Welt, die bislang im öffentlichen Diskurs noch zu wenig Beachtung gefunden hat. Er ist ein wichtiges Werk für Medizinal- und Gesundheitsfachpersonen, Juristinnen und Juristen, Verbände, Ethikkommissionen, Politik, Patientenvertretungen, Vertretungen der Kranken- und Invalidenversicherung, Industrie und alle, die sich mit Seltenen Krankheiten befassen. Die Beiträge sind im Rahmen des Zertifikatsstudiengangs «CAS Rare Diseases» der Universität Zürich entstanden. Der Weiterbildungsstudiengang dient u.a. als Plattform für Seltene Krankheiten, fördert den fundierten Austausch zwischen Fachpersonen und vermittelt den Teilnehmenden aus einer interdisziplinären Sichtweise Wissen nach dem aktuellsten Stand.

26 August 2026 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
PDF file
ARAlyssa L. Rippert
Alyssa L. Rippert
GAGudny Anna Arnadottir
Gudny Anna Arnadottir
LBLaura Bedinger
Laura Bedinger
Nicola Brunetti-PierriNicola Brunetti-Pierri
Nicola Brunetti-Pierri
JCJennifer Cech
Jennifer Cech
KIKosuke Izumi
Kosuke Izumi
LRP1 encodes the low‐density lipoprotein (LDL) receptor‐related protein 1 (LRP1), a transmembrane protein involved in endocytosis and activation of multiple signaling pathways. LRP1 variants have been implicated in the pathogenesis of congenital heart defects (CHD), Alzheimer's disease, and neurodevelopmental disorders (NDD). Biallelic LRP1 variants have also been reported in two siblings with CHD, hypotonia, dysmorphology, corneal clouding, and ascites. However, conclusive evidence supporting the role of LRP1 in human disease is still lacking. Individuals with heterozygous variants in LRP1 (NM_002332.3) were identified through genetic testing. GeneMatcher facilitated identification of participants and international collaboration. Comprehensive clinical and genotypic data were collected. Fifteen participants with heterozygous predicted loss‐of‐function (pLOF) or missense variants in LRP1 were identified. The most common phenotypes include NDD, CHD, musculoskeletal and gastrointestinal issues, and dysmorphic features. CHD was more common in participants with pLOF variants. Our findings suggest that LRP1 haploinsufficiency is associated with a syndromic NDD. Phenotypic differences in cardiac and neurologic involvement between participants with pLOF and missense variants suggest the possibility of alternate disease mechanisms.